Top videos

Coming to Dana-Farber as a Young Adult | Dana-Farber Cancer Institute
Coming to Dana-Farber as a Young Adult | Dana-Farber Cancer Institute administrator 5 Views • 2 years ago

Christina Dixon, who was 22 when diagnosed with Hodgkin lymphoma, looks back on her experience coming to Dana-Farber Cancer Institute as a young adult.

Learn more about Dana-Farber's Young Adult Program by visiting
www.dana-farber.org/youngadults.

Music: "Tell Me" by Alialujah Choir


Transcription:


When I came to Dana-Farber for the first time, it was really scary. I was 22 and had just found out about the diagnosis, and I really didn’t know what to expect. Once I found out about my diagnosis, it was actually just a day before I came in and met Dr. Fischer. When I came in for my first infusion appointment, I started out by going to lab services, where they checked me in and gave me schedule for what I would be doing for the day, and walked me through exactly where I would need to go and who I would be meeting with. I was really impressed with how organized everything was, but also how nice and caring everyone was.

When I met Kerry for the first time, I walked in and she had a big smile on her face and welcomed me and told me exactly where I was going to be going. I just immediately felt like she was going to be a really important person in my treatment. Kerry was very patient with me and explained to me exactly what I would be doing. She took my initial labs, and I found out that she would be my infusion nurse for most of my treatments. Kerry really inspired me to never lose my sense of humor regardless of the circumstances, and I’ll never forget how she was just always very positive.

So, when I met Dr. Fischer, I sat down with him and we talked through what he had seen from the biopsy and what he believed was the best treatment for my cancer. He was very, very patient with me, and I walked in with a lot of questions, and he went through each question with me and took time to help me understand what the side effects would be and what to expect. I had a lot of confidence in both Dana-Farber and specifically Dr. Fischer as my doctor. He would stop by every chemo appointment and ask how I was doing and make sure if there that was really bothering me, he would help me figure out a solution to it.

In a very scary time, they were able to make me feel much more secure. The more I came, the more I got to know them and they got to know me, and as they realized what kind of personality I have, they were able to give me advice that was very effective and that was specific to my personality type.

When I transitioned to surveillance, it was the most difficult experience of my life, and I wasn’t expecting that. Because they knew me, they were able to steer me in the right direction in terms of finding resources, whether it was talking to social workers or getting involved with the young adult program, and that ended up being a really important of my cancer experience.

I met with a couple of different people in the program—specifically Karen [Faciano 03:01], who helped me find a place where I was able to contribute and meet other young adults. I found about the annual conference and attended that, and through some of the workshops met other young adults. For the first time, I realized that the things that I was struggling with were completely normal and that I wasn’t the only one who felt isolated because of cancer.

At the time, Karen and the young adult team—they were developing the online platform to help young adults at Dana-Farber connect to each other. I was able to attend the focus groups on that and help in designing the website, and that was really meaningful to be a part of that.

At the end of treatment, I was really scared, because I was afraid that the support I had had during treatment was going to end, and I quickly realized that my care team here for me whenever I needed any support or help. I immediately began to feel a sense of freedom, that I could go out and do the things that I was afraid the cancer would take away from me.

Firm Foundation (He Won’t) [feat. Chandler Moore & Cody Carnes] | Maverick City Music | TRIBL
Firm Foundation (He Won’t) [feat. Chandler Moore & Cody Carnes] | Maverick City Music | TRIBL administrator 4 Views • 2 years ago

Official Music Video for Firm Foundation (He Wont) featuring Chandler Moore & Cody Carnes.

Firm Foundation (He Wont) was written by Chandler Moore, Cody Carnes & Austin Davis. This video was captured in Chicago, IL during Maverick City’s national tour October 1st, 2021.

You can stream Firm Foundation (He Wont) Now!
Link:
https://orcd.co/firmfoundation

Follow us on socials:
Instagram: https://www.instagram.com/triblmusic/
Facebook - https://www.facebook.com/triblmusic/
Twitter - https://twitter.com/triblmusic
Official Website- https://www.tribl.com/

Lyrics

Verse 1
Christ is my firm foundation
The Rock on which I stand
When everything around me is shaken I've never been more glad
That I put my faith in Jesus
'Cause He's never let me down
He's faithful through generations
So why would He fail now?

Verse 2
I've still got joy in chaos
I've got peace that makes no sense So I won't be going under
I'm not held by my own strength 'Cause I build my life on Jesus He's never let me down
He's faithful in еvery season
So why would He fail now?
Chorus
He won't He won't He won't fail He won't fail

Bridge
Rain came and wind blew
But my house was built on You I'm safe with You
I'm gonna make it through
I'm gonna make it through
'Cause I'm standing strong on You I'm gonna make it through
'Cause my house is built on You

Tag
No, He won't

Follow us on socials:
Instagram: https://www.instagram.com/triblmusic/
Facebook - https://www.facebook.com/triblmusic/
Twitter - https://twitter.com/triblmusic
Official Website- https://www.tribl.com/

#FirmFoundation #HeWont #MaverickCityMusic #Tribl

Cancer के दौरान Body में Swelling क्यों होती है ? | Boldsky
Cancer के दौरान Body में Swelling क्यों होती है ? | Boldsky administrator 5 Views • 2 years ago

सूजन के कारण त्‍वचा प‍िलप‍िली हो जाती है या हाथ दबाने पर गड्डा बन जाता है ज‍िससे पता चलता है क‍ि उस ह‍िस्‍से में सूजन है। सूजन कोई बीमारी नहीं है पर दूसरी बीमार‍ियों के कारण सूजन आ सकती है ज‍िसमें से एक है कैंसर। कैंसर के मरीजों के शरीर में अक्‍सर सूजन की श‍िकायत होती है। कई बार सूजन का कारण ब्‍लड क्‍लॉट न‍िकलता है इसल‍िए कैंसर के मरीज को सूजन है तो डॉक्‍टर से सलाह जरूर लें। पैरों की सूजन कम करने के ल‍िए आप मरीज के पैर या हाथ में माल‍िश भी कर सकते हैं। माल‍िश से ब्‍लड सर्कुलेशन बेहतर होता है। इस वीडियो में हम कैंसर के दौरान सूजन दूर करने के देसी तरीके और कैंसर में सूजन का कारण जानेंगे।

#CancerSwelling #SwellingRemedies
--------------------------------------------------------------------------------------------------------------

Subscribe to Boldsky Channel for latest updates.

https://www.youtube.com/channe....l/UCp0PDmU9L_rqiD4nD

Follow us on Twitter
https://twitter.com/boldskyliving

Like us on Facebook
https://www.facebook.com/boldsky.com/

Download App: https://play.google.com/store/....apps/details?id=in.o

Aefat- Proyecto de investigación- Clínica Universidad de Navarra (ataxia telangiectasia)
Aefat- Proyecto de investigación- Clínica Universidad de Navarra (ataxia telangiectasia) administrator 6 Views • 2 years ago

Aefat, la asociación que agrupa a las familias con afectados por ataxia telangiectasia en España, financia este proyecto de investigación que se desarrolla desde 2018 en la Clínica Universidad de Navarra.

Dirigido por los investigadores Borja Sáez y Felipe Prósper, el proyecto busca un tratamiento que solvente el problema de la inmunodeficiencia primaria de los afectados, limitando la predisposición a infecciones recurrentes y al desarrollo de tumores hematológicos.

En este proyecto, pionero en España, están implicados distintos especialistas de las áreas de terapia celular y terapia génica, y la unidad de trasplante hematopoyético de la Clínica Universidad de Navarra.

Aefat, con el apoyo de las familias y su entorno, voluntarios y colaboradores, continúa organizando eventos deportivos y culturales solidarios para seguir recaudando fondos para investigar esta enfermedad.

Con la colaboración de Zurich, la asociación participa con algunos de sus niños y jóvenes afectados en las maratones de Sevilla, Barcelona, San Sebastián y Málaga (patrocinadas por la compañía aseguradora).

Aefat también organiza desde hace siete años el festival solidario Aitzina Folk en Vitoria-Gasteiz y desde hace cuatro, la carrera solidaria “Tus pasos mueven el mundo” en Málaga, además de participar en otras competiciones deportivas.

¿QUÉ ES LA ATAXIA TELANGIECTASIA? La ataxia telangiectasia (AT o A-T) se manifiesta habitualmente antes de los dos años de edad. Afecta a las funciones de diferentes órganos y provoca incapacidad de coordinar movimientos, pérdida progresiva de movilidad (hacia los 9 años se necesita silla de ruedas), dificultad en el habla, estancamiento en el crecimiento, inmunodeficiencia, envejecimiento prematuro, dificultades para comer, problemas en la piel y en la visión, neumonías y otras complicaciones. La enfermedad está causada por una mutación en el gen ATM, localizado en el cromosoma 11, y que codifica para una proteína fosfatidilinositol-3-kinasa. Los pacientes son más proclives a los tumores malignos (como los sarcomas, linfomas, leucemias...).

Los enfermos son plenamente conscientes de su enfermedad, ya que no afecta a sus facultades mentales, pero la AT les impide realizar de forma independiente las actividades básicas de la vida diaria como vestirse, realizar su higiene personal, alimentarse, etc. Aun así, no hay que olvidar que tienen capacidad para pensar, sentir, amar y, por supuesto, para ser felices.

¿QUÉ ES AEFAT? Aefat es una asociación sin ánimo de lucro creada en 2009 y declarada de utilidad pública desde 2014, que está formada por familiares y personas relacionadas con enfermos de ataxia telangiectasia de diferentes puntos de España. También mantiene contacto cercano con las familias de afectados en Iberoamérica, y se relaciona con asociaciones similares europeas y americanas. Aefat pertenece a FEDER (Federación Española de Enfermedades Raras) y FEDAES (Federación de Ataxias de España).


www.aefat.es

The Incidence of Cutaneous T-Cell Lymphoma Seems to Be Higher in Veterans
The Incidence of Cutaneous T-Cell Lymphoma Seems to Be Higher in Veterans administrator 6 Views • 2 years ago

Stefan M. Schieke, MD, Assistant Professor of Dermatology at University of Wisconsin-Madison discusses cutaneous T-cell lymphoma (CTCL) in special populations such as African Americans and veterans of war.

According to a paper published in U.S. Medicine, “The Veterans Affairs (VA) classifies CTCL and other non-Hodgkin lymphomas as presumptively caused by Agent Orange exposure or service in the Vietnam theater, even without exposure to the problematic herbicide. Both arise at markedly elevated rates in veterans, but it had remained unknown just how much higher the rate of CTCL was.”

In a study published in the Journal of Investigative Dermatology, researchers noted that “an estimated 5-15% of all CTCL diagnosed each year occurs in veterans, a percentage far greater than the percentage of veterans in the total U.S. population.” The researchers hypothesized that as the Surveillance, Epidemiology, and End Results (SEER) Program, the main source of data for national disease incidence, excludes cases from VAMCs, the incidence of CTCL in the U.S. might be underreported.1

Researchers found a 6 to 8 times higher incidence of CTCL in veterans than in the general population. The demographics and trends in the number of CTCL patients per conflict era showed great variations. Our data changes the CTCL incidence trends in the US.

The findings suggest that specific military exposures, such as Agent Orange during the Vietnam War, may be potential pathogenic drivers and warrant further exploration of the causes behind increased incidence of CTCL in veterans.

Cutaneous T-cell lymphoma belongs to the non-Hodgkin lymphoma class of hematologic T-cell lymphoproliferative disorders. Cutaneous T-cell lymphoma is a rare group of malignancies, with an incidence of 6.4 cases per 1 million people. This form of T-cell lymphoma represents around 70% of primary cutaneous lymphomas.

Cutaneous T-cell lymphoma attacks the the body’s immune system, specifically, the lymphatic system, affecting the two types of white blood cells (lymphocytes): B-cells and T-cells. Whereas the B-lymphocytes act to neutralize the pathogens, the main job of the T-lymphocytes is to attach to these foreign cells, viruses, or cancerous growths, and directly destroy them.

Compared with other T-cell lymphomas, a distinguishing feature of CTCL is implied by the name: malignant T-cells migrating to, and collecting in, cutaneous tissue. Diagnosis can be challenging, because the initial signs and symptoms are largely skin-related and overlap with those of many other dermatologic disorders. Adding to the challenge, CTCL variants present with overlapping symptomatology, and correct identification of the CTCL subtype is key to both treatment and prognosis. Histopathologic features must be correlated with the clinical presentation to confirm the diagnosis.

Many forms of CTCL are relatively indolent compared with other T-cell lymphomas, but there are aggressive subtypes. This is illustrated by the two most common forms of CTCL: mycosis fungoides and Sézary syndrome. Although mycosis fungoides is considered a slow-growing variant, Sézary syndrome is aggressive and generally has a poor prognosis. Importantly, even the indolent subtypes can progress in some patients and become difficult to manage.


References
Boyle, A: CTCL 6-10 Times More Common in Veterans; Agent Orange a Factor New Therapies Raise Optimism about Treatment. US Medicine June 12, 2018.

Del Guzzo C, Levin A, Dana A, Vinnakota R, Park Y, Newman J, Langhoff E, Geskin L. 133: The incidence of cutaneous T-cell lymphoma in the veteran population. JID. 2016May;136(5):S24.

HIV/AIDS: Plague of the 21st Century
HIV/AIDS: Plague of the 21st Century administrator 4 Views • 2 years ago

In the 1980s, HIV began spreading throughout North America and the world at large. From "gay cancer" to the myth of Patient Zero, these are some of the stories that emerged from those first few years.

→ Subscribe for new videos four times per week.
https://www.youtube.com/c/biog....raphics?sub_confirma

TopTenz Properties
Our companion website for more: http://biographics.org
Our sister channel TopTenz: https://www.youtube.com/channe....l/UCQ-hpFPF4nOKoKPEA
Our Newest Channel about Interesting Places: https://studio.youtube.com/cha....nnel/UCHKRfxkMTqiiv4

Source/Further reading:

The Basics of HIV and AIDS:
https://www.hiv.gov/hiv-basics
https://www.ncbi.nlm.nih.gov/p....mc/articles/PMC32344

CDC Opportunistic Infections:
https://www.cdc.gov/hiv/basics..../livingwithhiv/oppor

CDC Incidence rates by population sub-groups:
https://www.cdc.gov/hiv/basics/statistics.html
https://www.census.gov/quickfa....cts/fact/table/US/PS

AIDS/HIV origins and history:
https://www.healthline.com/health/hiv-aids/history
https://www.hiv.gov/hiv-basics/overview/history/hiv-and-aids-timeline
https://jech.bmj.com/content/67/6/473
https://www.nature.com/articles/nature19827
https://hivhistory.org/panels/panel-01/
https://www.the-scientist.com/....daily-news/hiv-sprea

The Story of Gaetan Dugas:
https://www.lrb.co.uk/the-pape....r/v40/n18/tom-crewe/
https://www.scribd.com/book/414171918
https://www.scribd.com/book/240406939
https://www.scribd.com/book/362833379

HIV/AIDS Today in Africa:
https://www.unaids.org/en/reso....urces/presscentre/pr
20AIDS%20mortality%20levels.
https://aids2020.unaids.org/ch....apter/region-profile

Showing 76 out of 703